Global Tinea Pedis Treatment Market Report 2024

The tinea pedis treatment market size has grown strongly in recent years. It will grow from $1.29 billion in 2023 to $1.36 billion in 2024 at a compound annual growth rate (CAGR) of 6%. The historical growth can be attributed to several factors, including the rising incidence of infectious disorders, utilization of ancient remedies, discovery of antifungals, availability of Over-the-Counter (OTC) products, and advancements in medical education.

The tinea pedis treatment market size is expected to see strong growth in the next few years. It will grow to $1.73 billion in 2028 at a compound annual growth rate (CAGR) of 6.2%. The anticipated growth in the forecast period can be attributed to factors such as globalization, increased travel, drug resistance, economic influences, and public health campaigns. Major trends expected in the forecast period include innovative drug delivery systems, advancements in medical technology, developments in pharmaceutical technology, and progress in nanotechnology.

The increasing frequency of foot and ankle injuries is poised to drive the expansion of the tinea pedis treatment market in the coming years. Foot and ankle injuries encompass damage or trauma to the bones, ligaments, tendons, muscles, or other tissues in the foot or ankle area, often resulting from accidents, sports activities, or repetitive stress. Various factors, including changes in lifestyle, heightened participation in sports and physical activities, improper footwear, incorrect training methods, susceptibility to falls, and degenerative conditions, contribute to foot and ankle injuries. Additionally, the prevalence of obesity and chronic diseases such as diabetes heightens the risk of foot and ankle complications. Such injuries can exacerbate tinea pedis treatment by creating conducive conditions for fungal growth and prolonging periods of inactivity. For instance, in November 2023, Howden Group Holdings Ltd reported a 170% increase in the severity of ankle injuries in the English Premier League from October 2022 to January 2023 following the FIFA World Cup Qatar 2022. Therefore, the rising incidence of foot and ankle injuries propels the tinea pedis treatment market.

The growing prevalence of fungal infections is anticipated to fuel the growth of the tinea pedis treatment market in the future. Fungal infections are caused by fungi and can affect various body parts. Factors contributing to the prevalence of fungal infections include compromised immune status, environmental conditions favoring fungal growth, fungal exposure, underlying health conditions, occupational exposure, and personal hygiene practices. Treatment for tinea pedis aims to eradicate the fungal infection and alleviate associated symptoms. For example, according to the Centers for Disease Control and Prevention (CDC), fungal infection-related hospitalizations totaled 59,212 by 2021, with the hospitalization rate increasing from 25 in 2020 to 26.8 in 2021 per 10,000 hospitalizations, representing an average annual increase of 8.5%. Hence, the rising prevalence of fungal infections fuels the expansion of the tinea pedis treatment market.

Major players in the tinea pedis treatment market are developing comprehensive formulations for controlling skin infections, aiming to improve patient outcomes. These formulations provide holistic solutions by addressing the fungal infection, preventing its recurrence, and managing associated symptoms such as itching, scaling, and redness. For example, in May 2022, Bayer, a pharmaceutical company based in Germany, introduced an innovative and enhanced line of Canesten products. These formulations effectively alleviate itching and hinder the further spread of infection. Canesten cream offers relief for conditions such as ringworm, jock itch, athlete's foot, skin candidiasis, erythrasma, and various fungal infections. With clotrimazole as the active ingredient, it targets the fungal infection responsible for athlete's foot. Clotrimazole disrupts fungal growth, thus alleviating symptoms such as itching, burning, and skin irritation commonly associated with tinea pedis.

Major companies operating in the tinea pedis treatment market are McKesson Corporation, Pfizer Inc., Bayer AG, Novartis AG, GlaxoSmithKline plc, Sandoz International GmbH, Bausch Health Companies Inc., Perrigo Company plc, Aurobindo Pharma, Dr. Reddy's Laboratories Ltd., Cipla Ltd., Lupin Limited, Glenmark Pharmaceuticals Ltd., Almirall S.A., Exeltis USA Inc., Taro Pharmaceutical Industries Ltd., Tolmar Pharmaceuticals Inc., Sebela Pharmaceuticals Inc., Ego Pharmaceuticals Pty. Ltd., Fougera Pharmaceuticals Inc., Camber Pharmaceuticals Inc, Mayne Pharma Group Limited, Sun Pharmaceutical Industries Ltd., CorePharma LLC, Blueberry Therapeutics Ltd.

North America was the largest region in the tinea pedis treatment market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the tinea pedis treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the tinea pedis treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tinea pedis treatment encompasses various medical interventions and self-care practices aimed at alleviating symptoms and eradicating the fungal infection known as athlete's foot. Antifungal drugs, available in both topical and oral forms, are commonly utilized to eliminate the fungus causing the infection and reduce symptoms such as itching, redness, and inflammation, thereby preventing the spread of the infection to other parts of the body.

The primary drug classes used in tinea pedis treatment include antifungals and combinations. Antifungals are substances or medications specifically designed to kill or inhibit the growth of fungi responsible for tinea pedis. They can be administered orally or topically to treat interdigital tinea pedis, plantar tinea pedis, and vesicular tinea pedis indications. These medications are distributed through various channels including hospital pharmacies, retail pharmacies, and e-commerce platforms.

The tinea pedis treatment market research report is one of a series of new reports that provides tinea pedis treatment market statistics, including tinea pedis treatment industry global market size, regional shares, competitors with a tinea pedis treatment market share, detailed tinea pedis treatment market segments, market trends and opportunities, and any further data you may need to thrive in the tinea pedis treatment industry. This tinea pedis treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The tinea pedis treatment market consists of revenues earned by entities by providing services such as self-care measures, over-the-counter antifungal medications, prescription-strength medications, education and prevention. The market value includes the value of related goods sold by the service provider or included within the service offering. The tinea pedis treatment market also includes sales of antifungal medications, steroid creams, powders, sprays. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.